A Study to Evaluate Two Vonoprazan Orally Disintegrating Tablet Formulations Administered Without Water or Mixed With Water and Administered Via a Syringe Relative to the Vonoprazan Tablet in Healthy Participants

A Phase 1, Open-Label, Randomized, Single-Dose, 5-Period Crossover Study to Determine the Bioavailability of Two Vonoprazan Orally Disintegrating Tablet Formulations Administered Without Water or Mixed With Water and Administered Via a Syringe Relative to the Vonoprazan Tablet in Healthy Subjects

The primary objective of this study is to assess the bioavailability (BA) of a single oral dose of two vonoprazan orally disintegrating tablet formulations (ODT-1 or ODT-2) administered without water or mixed with water and administered via a syringe relative to the vonoprazan tablet in healthy participants.

Study Overview

• Status: Completed
• Conditions: Healthy Volunteers
• Intervention / Treatment: Drug: Vonoprazan ODT-1 or ODT-2 without Water; Drug: Vonoprazan ODT-1 or ODT-2 with Water; Drug: Vonoprazan (Reference)

• Study Type: Interventional
• Enrollment (Actual): 25
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Texas
    • Austin, Texas, United States, 78744
      • 7551 Metro Center Dr Ste 200

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• The participant is 18 to 55 years of age, inclusive, at Screening.
• The participant has a body mass index (BMI) 18 to 32 kg/m2, inclusive, at Screening.
• The participant is considered by the investigator to be in good general health as determined by medical history, clinical laboratory test results, vital sign measurements, 12-lead electrocardiogram (ECG) results, and physical examination findings at Screening.
• Female participants of reproductive potential must use an acceptable method of birth control (ie, diaphragm with spermicide, intrauterine device, condom with foam or vaginal spermicide, oral contraceptives, or abstinence) from signing the informed consent form (ICF) until 4 weeks after the last dose of study drug or be surgically sterile (ie, hysterectomy or bilateral oophorectomy) or postmenopausal (defined as amenorrhea for 12 consecutive months and documented plasma follicle stimulating hormone [FSH] level >40 IU/mL during Screening).
• Female participants must have a negative pregnancy test at Screening and upon Check-in.
• The participant agrees to comply with all protocol requirements.
• The participant is able to provide written informed consent.

Exclusion Criteria:

• The participant has a positive test result for hepatitis B surface antigen, hepatitis C virus antibody, or human immunodeficiency virus types 1 or 2 antibodies at Screening.
• The participant has a positive test result for the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at Check-in.
• The participant has a history of a clinically significant neurological, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, or endocrine disease or other abnormality that may impact the ability of the subject to participate.
• The participant has current or recent (within 6 months) gastrointestinal conditions that would be expected to influence the absorption of drugs (eg, history of malabsorption, esophageal reflux, peptic ulcer disease, erosive esophagitis (EE)), frequent (more than once per week) occurrence of heartburn, or any surgical intervention.
• The participant has any other clinically significant findings on physical examination, clinical laboratory abnormalities, and/or ECG results that preclude his/her participation in the study, as deemed by the investigator.
• The participant has used any prescription (excluding hormonal birth control) and/or over-the-counter medications (including Cytochrome P450 3A4 (CYP3A4) inducers) except acetaminophen (up to 2 g per day), including herbal or nutritional supplements, within 14 days before the first dose of study drug, and/or is expected to require any such medication during the course of the study until the end of confinement on Study Day 23.
• The participant has consumed grapefruit and/or grapefruit juice, Seville orange or Seville orange-containing products (eg, marmalade), or other food products that may be CYP3A4 inhibitors (eg, vegetables from the mustard green family [kale, broccoli, watercress, collard greens, kohlrabi, Brussels sprouts, mustard] and charbroiled meats) within 7 days before the first dose of study drug and/or is expected to be unable to abstain through the study.
• The participant has consumed caffeine- or xanthine-containing products within 48 hours (or 5 half-lives) before the first dose of study drug and/or is unable to abstain through the study.
• The participant is a smoker and/or has used nicotine or nicotine-containing products (eg, snuff, nicotine patch, nicotine chewing gum, mock cigarettes, or inhalers) within 6 months before the first dose of study drug.
• The participant has a history of alcohol abuse and/or drug addiction within the last year or excessive alcohol consumption (regular alcohol intake >21 units per week for male subjects and >14 units of alcohol per week for female subjects; 1 unit is equal to approximately ½ pint [200 mL] of beer, 1 small glass [100 mL] of wine, or 1 measure [25 mL] of spirits) or use of alcohol 48 hours before the first dose of study drug.
• The participant has a positive test result for drugs of abuse, alcohol, or cotinine (indicating active current smoking) at Screening or Check-in.
• The participant is involved in strenuous activity or contact sports within 24 hours before the first dose of study drug and during the study.
• The participant has donated blood or blood products >450 mL within 30 days before the first dose of study drug.
• The participant has a history of relevant drug and/or food allergies (ie, allergy to vonoprazan or excipients or any significant food allergy that could preclude a standard diet in the clinical unit).
• The participant has received a study drug in another investigational study within 5-times the t1/2 of the study drug or 30 days of dosing, whichever is longer.
• Female participants who are pregnant or lactating; intend to become pregnant before, during, or within 4 weeks after participating in this study; or intend to donate ova during this time period.
• The participant is not suitable for entry into the study in the opinion of the investigator.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

5

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Sequence A, B, C, D, E: Vonoprazan 10 mg; Participants will be randomly assigned to 1 of 5 treatment sequences in a 1:1:1:1:1 ratio. On the first day of each dosing period, participants will receive 1 of the following study treatments according to the treatment sequence they are randomly assigned to: Treatment A: Vonoprazan 10 mg ODT-1 without water; Treatment B: Vonoprazan 10 mg ODT-1 mixed with water and administered via a syringe; Treatment C: Vonoprazan 10 mg ODT-2 without water; Treatment D: Vonoprazan 10 mg ODT-2 mixed with water and administered via a syringe; Treatment E (reference): Vonoprazan 10 mg tablet. There will be a washout interval of a minimum of 5 days between study drug dosing in each period.	Drug: Vonoprazan ODT-1 or ODT-2 without Water; Vonoprazan will be administered orally as an ODT-1 or ODT-2 without water; Drug: Vonoprazan ODT-1 or ODT-2 with Water; Vonoprazan will be administered orally as an ODT-1 or ODT-2 with water via a syringe; Drug: Vonoprazan (Reference); Vonoprazan will be administered orally as a tablet
Experimental: Sequence B, D, E, C, A: Vonoprazan 10 mg; Participants will be randomly assigned to 1 of 5 treatment sequences in a 1:1:1:1:1 ratio. On the first day of each dosing period, participants will receive 1 of the following study treatments according to the treatment sequence they are randomly assigned to: Treatment A: Vonoprazan 10 mg ODT-1 without water; Treatment B: Vonoprazan 10 mg ODT-1 mixed with water and administered via a syringe; Treatment C: Vonoprazan 10 mg ODT-2 without water; Treatment D: Vonoprazan 10 mg ODT-2 mixed with water and administered via a syringe; Treatment E (reference): Vonoprazan 10 mg tablet. There will be a washout interval of a minimum of 5 days between study drug dosing in each period.	Drug: Vonoprazan ODT-1 or ODT-2 without Water; Vonoprazan will be administered orally as an ODT-1 or ODT-2 without water; Drug: Vonoprazan ODT-1 or ODT-2 with Water; Vonoprazan will be administered orally as an ODT-1 or ODT-2 with water via a syringe; Drug: Vonoprazan (Reference); Vonoprazan will be administered orally as a tablet
Experimental: Sequence C, E, B, A, D: Vonoprazan 10 mg; Participants will be randomly assigned to 1 of 5 treatment sequences in a 1:1:1:1:1 ratio. On the first day of each dosing period, participants will receive 1 of the following study treatments according to the treatment sequence they are randomly assigned to: Treatment A: Vonoprazan 10 mg ODT-1 without water; Treatment B: Vonoprazan 10 mg ODT-1 mixed with water and administered via a syringe; Treatment C: Vonoprazan 10 mg ODT-2 without water; Treatment D: Vonoprazan 10 mg ODT-2 mixed with water and administered via a syringe; Treatment E (reference): Vonoprazan 10 mg tablet. There will be a washout interval of a minimum of 5 days between study drug dosing in each period.	Drug: Vonoprazan ODT-1 or ODT-2 without Water; Vonoprazan will be administered orally as an ODT-1 or ODT-2 without water; Drug: Vonoprazan ODT-1 or ODT-2 with Water; Vonoprazan will be administered orally as an ODT-1 or ODT-2 with water via a syringe; Drug: Vonoprazan (Reference); Vonoprazan will be administered orally as a tablet
Experimental: Sequence D, C, A, E, B: Vonoprazan 10 mg; Participants will be randomly assigned to 1 of 5 treatment sequences in a 1:1:1:1:1 ratio. On the first day of each dosing period, participants will receive 1 of the following study treatments according to the treatment sequence they are randomly assigned to: Treatment A: Vonoprazan 10 mg ODT-1 without water; Treatment B: Vonoprazan 10 mg ODT-1 mixed with water and administered via a syringe; Treatment C: Vonoprazan 10 mg ODT-2 without water; Treatment D: Vonoprazan 10 mg ODT-2 mixed with water and administered via a syringe; Treatment E (reference): Vonoprazan 10 mg tablet. There will be a washout interval of a minimum of 5 days between study drug dosing in each period.	Drug: Vonoprazan ODT-1 or ODT-2 without Water; Vonoprazan will be administered orally as an ODT-1 or ODT-2 without water; Drug: Vonoprazan ODT-1 or ODT-2 with Water; Vonoprazan will be administered orally as an ODT-1 or ODT-2 with water via a syringe; Drug: Vonoprazan (Reference); Vonoprazan will be administered orally as a tablet
Experimental: Sequence E, A, D, B, C: Vonoprazan 10 mg; Participants will be randomly assigned to 1 of 5 treatment sequences in a 1:1:1:1:1 ratio. On the first day of each dosing period, participants will receive 1 of the following study treatments according to the treatment sequence they are randomly assigned to: Treatment A: Vonoprazan 10 mg ODT-1 without water; Treatment B: Vonoprazan 10 mg ODT-1 mixed with water and administered via a syringe; Treatment C: Vonoprazan 10 mg ODT-2 without water; Treatment D: Vonoprazan 10 mg ODT-2 mixed with water and administered via a syringe; Treatment E (reference): Vonoprazan 10 mg tablet. There will be a washout interval of a minimum of 5 days between study drug dosing in each period.	Drug: Vonoprazan ODT-1 or ODT-2 without Water; Vonoprazan will be administered orally as an ODT-1 or ODT-2 without water; Drug: Vonoprazan ODT-1 or ODT-2 with Water; Vonoprazan will be administered orally as an ODT-1 or ODT-2 with water via a syringe; Drug: Vonoprazan (Reference); Vonoprazan will be administered orally as a tablet

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximum Observed Drug Concentration (Cmax) of Vonoprazan	Cmax of Vonoprazan was reported.	Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose
Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Last Quantifiable Concentration (AUC0-t) of Vonoprazan	AUC0-t of Vonoprazan was reported.	Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose
AUC From Time 0 Extrapolated to Infinity (AUC0-inf) of Vonoprazan	AUC0-inf of Vonoprazan was reported.	Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time to Maximum Observed Plasma Concentration (Tmax) of Vonoprazan	Tmax of Vonoprazan was reported.	Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose
Time Until First Measurable Concentration in Plasma (Tlag) of Vonoprazan	Tlag of Vonoprazan was reported.	Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose
Terminal Elimination Rate Constant (λz) of Vonoprazan	λz of Vonoprazan was reported.	Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose
Terminal Phase Half-life (t1/2) of Vonoprazan	t1/2 of Vonoprazan was reported.	Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose
Apparent Oral Clearance (CL/F) of Vonoprazan	CL/F of Vonoprazan was reported.	Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose
Apparent Volume of Distribution (Vz/F) of Vonoprazan	Vz/F of Vonoprazan was reported.	Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose

Collaborators and Investigators

• Sponsor: Phathom Pharmaceuticals, Inc.
• Investigators: Study Director: Medical Director, Phathom Pharmaceuticals

Study record dates

Study Major Dates

• Study Start (Actual): February 14, 2025
• Primary Completion (Actual): April 5, 2025
• Study Completion (Actual): April 10, 2025

Study Registration Dates

• First Submitted: February 14, 2025
• First Submitted That Met QC Criteria: February 14, 2025
• First Posted (Actual): February 18, 2025

Study Record Updates

• Last Update Posted (Actual): December 19, 2025
• Last Update Submitted That Met QC Criteria: December 4, 2025
• Last Verified: December 1, 2025

More Information

Terms related to this study

• Keywords: Vonoprazan; Erosive Esophagitis; Non-erosive Gastroesophageal Reflux Disease
• Additional Relevant MeSH Terms: Inorganic Chemicals; Anions; Ions; Electrolytes; Hydroxides; Alkalies; Oxides; Oxygen Compounds; Water; 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine
• Other Study ID Numbers: VPED-105

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No